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Main Points:  
- Breast milk lactobacilli and bifidobacteria constitute a promising option for the 
improvement of infant formulas. 
- Supplementation of formula with breast-milk probiotics will allow the development of 
new products assisting in the establishment of a healthy microbiota and intestinal barrier. 
- In the near future it is likely we will witness the routine supplementation of infant formulas 























Breast-milk is the best food for infant nutrition and development, protecting the newborn against 
allergies and infections. The main difference between breast and formula-fed infants regards the 
higher level of Bifidobacterium in the gut microbiota of the former group. This has been 
traditionally attributed to the presence of bifidogenic compounds, but recent studies indicate 
the presence of lactic acid bacteria and also bifidobacteria in breast-milk. The isolation and 
characterisation of these breast-milk microorganisms would allow the inclusion of specifically-
selected bacteria in formulas targeted at both pre-term and full-term infants. This constitutes a 
very promising area for the development of new products aiming at assisting in the establishment 





The process of establishment and colonization of the infant gut is known to play an essential role 
for the maturation of the immune system and the establishment of the gut barrier [1]. Moreover, 
alteration in this process of colonization has been shown to predispose to disease later in life [2]. 
The factors driving gut colonization are diverse, among them the type of feeding is known to 
have a marked influence [3], with breast-milk being the best food for the infant. Breast-fed infants 
are protected against allergies, diarrhea, respiratory and gastrointestinal infections. Breast-
feeding also affects at the establishment and development of the gut microbiota in the 
newborn. The main difference between breast and formula-fed infants regards the higher levels 
of Bifidobacterium in the microbiota of the former group. This has been traditionally attributed to 
the presence of bifidogenic compounds in breast-milk [4]. But recent studies indicate the 
presence of lactic acid bacteria and bifidobacteria in breast-milk [5-7], which may also 
contribute to the dominance of the latter microorganism on the breast-fed infant microbiota. 
Therefore, breast-milk can be considered a synbiotic food, containing beneficial microorganisms 
and oligosaccharides [8] which may critically contribute to the establishment of a healthy 
microbiota in breast-fed infants.  
These facts have attracted the attention of the industry towards the supplementation of infant 
formula. The use of prebiotic oligosaccharides has been deeply investigated and currently it 
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constitutes a common practice on the manufacture of infant formulas. Attention has recently 
started to be paid to the addition of probiotics, and some strains have been included in formulas. 
Most of the currently used strains correspond to commercially available strains, not specifically 
selected to this end, which have not been isolated from the natural source. Only very recently 
bacteria isolated from breast-milk have gained attention as probiotics for driving or assisting in 
the development of the microbiota in the non-breast-fed infant.  
 
 
NEEDS AND OPPORTUNITIES AT THE NEONATAL UNIT 
 
Neonatal Units (NU) take care of newborns showing different problems at birth. Most of the work 
carried out at the NU relates to the care of preterm neonates (gestational age < 37 weeks). 
Among these infants those showing very low birth-weight (< 32 weeks and/or < 1500 g birth-
weight) constitute the most demanding group, as they often present health complications. 
Currently, any baby born with a gestational age over 23-24 weeks has true possibilities of survival, 
although mortality and morbidity in this group of infants is extremely high. 
At birth human beings are immature for most of their organs and functions. All the body systems 
must become mature during the first months of life to gain full functionality. Thus, these systems 
should adapt to extra-uterine life. In the preterm neonate this constitutes a very challenging 
process in which the gut microbiota establishment plays an important role. Feeding habits during 
the first days of life constitute a key point which will affect not only the health of the newborn, but 
also the future health of the individual [9,10]. 
There is a wide scientific consensus supporting breast-feeding as the ideal standard for the 
newborn between 0 and 6 months. In the case of the preterm infant, breast-feeding is often 
supplemented to complete the nutritional requirements [11]. Breast-feeding provides not only 
adequate nutrients with a high biodisponibility, but it also facilitates an appropriate colonization 
of the gastrointestinal tract. In addition to nutrients, breast-milk provides prebiotic substrates and 
potentially probiotic bacteria, which drive the process of development of the ideal gut 
microbiota. This last aspect, which is often not taken into consideration, may be one of the key 
determinants of the relationship observed between breast-feeding and protection against 
different diseases.  
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Unfortunately, despite of the general recommendation on breast-feeding, this is not always 
possible. For these situations infant formula manufacturers try to develop formulas whose 
composition resembles, as much as possible, that of the breast-milk. Adapted formulas, for both 
term and preterm infants, have improved significantly over the last years, reaching a high 
nutritional similarity to that of breast-milk. However, there is still lot of work to be done before they 
are equivalent in all aspects, mainly regarding their immunomodulatory properties. In this sense, 
infant formulas are still far from human milk as demonstrated by the increased risk of infection 
observed in the formula fed infant [12].   
For these reasons, current research efforts focus on obtaining improved formulas, closely 
resembling breast-milk also in their immunological properties, to achieve a reduction of infection 
risks [13]. At the NU, reducing the risk of infection is essential. An adequate, microbial colonization 
of the neonatal intestinal tract is critical to prevent infection and other health problems whose 
relationship with diet may be more important than previously considered constituting a task for 
future research [10].  
 
 
PROBIOTICS FOR NEONATES: NEEDS AND SOURCE OF ORIGIN 
 
Probiotics are defined as live microorganisms which when administered in adequate amounts 
confer a benefit on the host [14]. Different microorganisms are used as human probiotics, being 
Lactobacillus and Bifidobacterium the most frequently used genera. Most of the current 
commercial probiotic strains have not been selected for specific applications but rather selected 
on the basis of their technological potential. Nevertheless, it is well known that probiotic effects 
are strain specific, therefore it is very likely that better performing strains may be selected when a 
rational, use-specific, selection process is followed [15]. The selection of strains from appropriate 
sources depending on the target population, such as neonates, whose microbiota differ from 
that of adults, constitutes a promising approach. 
Infants are one of the populations that may benefit more from the use of probiotics. There is a 
critical “window period” during the first months of life where there is an important opportunity for 
immune education, when the intestinal microbiota and maturation of the immune system are not 
yet completed [16].  Several groups of infants: preterm, formula-fed, those who use antibiotics or 
require intensive care, have an increased risk of developing diseases. Such diseases, including 
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infections, necrotising enterocolitis or atopic eczema have been prevented by probiotics [3]. The 
main aim of probiotic intervention in these populations is to avoid and aberrant microbiota 
development which may led to impaired gut barrier function and abnormal immune 
responsiveness [17]. The inclusion of specifically-selected breast-milk bacteria in formulas 
constitutes a very promising area for the development of new products aiming at the 
establishment of a healthy gut microbiota and a proper intestinal barrier, resembling that of 
breast-fed infants [15]. Nevertheless, so far few strains have been specifically selected for human 
neonates, where the applications of probiotics may have a great positive impact [18]. 
 
 
BREAST-MILK LACTOBACILLI AS PROBIOTICS FOR NEONATES 
 
Lactobacilli are among the most abundant microbial genera of lactic acid bacteria found in 
human milk [6,19,20]. The probiotic potential of some lactobacilli isolated from breast-milk has 
been demonstrated. Relevant studies have been carried out characterizing the antimicrobial 
potential, survival to the simulated gastrointestinal conditions, adhesion to intestinal cell lines, and 
immunomodulatory properties of strains of L. salivarius, L. gasseri, and L. fermentum isolated from 
breast-milk [21,22]. Safety and oral tolerance assays indicated that some of these strains were 
adequate for human consumption [23]. This work constituted a pioneer example of the way from 
scientific demonstration of the probiotic potential to the commercial application of breast-milk 
strains in infant formulas and other products [24].  
Infant formulas and fermented dairy products for children do not seem to be the only target for 
the application of lactobacilli originating from breast-milk, and recent studies have also proven 
their usefulness in adults [25].  
Genetic tools, allowing sequencing and annotation of the whole genome of some of these 
microorganisms, as in the case of the genome of a breast-milk L. salivarius strain [26], will 
undoubtedly facilitate further studies on new functional probiotic properties and applications for 
these strains.   
 
 




As previously indicated, one of the main differences between breast and formula-fed infants is 
the dominance of bifidobacteria in the former group. It has been shown that allergic infants are 
often less colonised by bifidobacteria and present lower concentrations [27]. Interestingly, it has 
also been shown that allergic mothers show a lower concentration of breast-milk bifidobacteria 
than non-allergic ones, and their infants had lower levels of faecal bifidobacteria [28]. Thus, the 
early bifidobacterial composition appears to have an impact on the immune system. 
Interestingly, now we know that breast-milk contains bifidobacteria  [5,6,29]. Thus, breast-milk 
provides a constant supply of Bifidobacterium, which may contribute to the dominance of this 
microorganism in breast-fed infants. This brings interest to this specific microbial group, and it 
suggests that these microorganisms may constitute a better option for supplementation than 
other microorganisms which do not play a dominant role on the breast-fed newborn gut. In fact, 
increasing bifidobacterial levels has often being considered a target for the formulation and 
development of infant formula [4].  
The above mentioned facts have attracted the attention towards the isolation of bifidobacteria 
from breast milk. Some strains have already been isolated [5,6,7] with B. breve and B. longum 
being the species most frequently found, although other species such as B. bifidum and B. 
pseudocatenulatum have also been isolated. Therefore, these species constitute the prime 
choice species for the further selection of probiotic strains targeting neonates. In addition, some 
of the strains have been characterised and in vitro test have been conducted to determine their 
probiotic potential for neonates. The results indicate good adhesion ability for some of the breast-
milk Bifidobacterium strains. Interestingly, higher adhesion of some strains to intestinal mucus from 
younger infants was observed, indicating that adhesion to intestinal mucus varies depending on 
the infant’s age and strain. This underlines the potential for selection of strains specifically 
targeting young infants [18]. 
 
 
OTHER BREAST-MILK MICROORGANISMS AS PROBIOTICS FOR NEONATES 
 
To date, little is known about the potential health benefits (if they exist) that other breast-milk 
bacteria, different from bifidobacteria and lactobacilli, may have on the newborn. The search for 
strains able to exert beneficial effects has been mainly focused on the natural inhabitants of our 
gastrointestinal tract belonging to Bifidobacterium and Lactobacillus. However, a substantial and 
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recent body of scientific evidence suggests that other bacterial genera could rationally be 
screened for their use as probiotics [30]. Interestingly, members of the genera Staphylococcus 
and Streptococcus comprise up to 90% of the total microbial strains isolated from human milk 
[6,31]. This pool of enterococci, staphylococci and streptococci provides a continuous source of 
microbial inoculation for the breast-fed infant gut. Therefore, it is plausible and reasonable to 
think that due to the levels at which they are ingested, these microorganisms might play 
important roles in the infant development.  
Obviously, a major safety concern appears immediately: the presence of pathogen 
representatives within these taxa. Typically, streptococci and staphylococci strains isolated from 
human breast-milk lack the genetic determinants coding for virulence factors, and are 
susceptible to a high number of antibiotics [31,32]. This lack of virulence factors and the higher 
sensitivity to antibiotics create a clearly differentiated barrier between the commensal 
microbiota of the human breast-milk and their pathogen relatives. Care should be taken about 
the presence antibiotic resistances and virulence factors encoded in mobile genetic elements, 
since they may be transferred from pathogenic to commensal strains through horizontal gene 
transfer. This mechanism must be clearly evaluated prior to the final strain selection. In addition, 
the establishment of differential phenotypic and genotypic traits that may group this commensal 
microbiota apart from their pathogen relatives is mandatory. 
It is thus conceivable that the more abundant microorganisms of human milk might have 
important functions in the development of the infant gut. Even in certain cases these bacteria, 
with the appropriated methodology of selection, could be prospected for potential and specific 





Human breast-milk constitutes an interesting source for obtaining new and specific probiotic 
strains for neonates, aiming at assisting a proper development of the gut microbiota and the 
immune development in infants who, for different reasons, cannot be breast-fed.  
Although clinical data would be needed before drawing any conclusion on their probiotic 
properties, some of the strains isolated from breast-milk may have good probiotic potential for 
their inclusion in infant formula. To this regard, the further improvement of the formula 
9 
 
composition constitutes a scientific challenge as well as a future opportunity to improve the 
health status of the neonate. It is also important to underline that infants constitute a highly 
susceptible population. Therefore, although the currently available data on probiotics indicate a 
good tolerability and safe consumption, a detailed safety assessment would be needed before 
any new strain is included in infant formula. 
In the near future it is likely that we will witness routine supplementation of infant formulas with 
specifically selected probiotic strains isolated from breast-milk. To closely resemble the natural 
scenario, these supplements should not include exclusively lactobacilli and bifidobacteria, but 
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